ASCLETIS-B (1672.HK) announcement commentary: The combination of ASC47 and semaglutide shows superior weight loss effects in obese mouse models.

Event: The company released experimental data on the fat-reducing and muscle-building treatment drug ASC47 in combination with semaglutide in obese mice. This drug is a thyroid hormone receptor β agonist targeting fat and is administered via subcutaneous injection once a month.

Everbright17minutes ago

Repurchase summary on December 20 | TENCENT, HSBC Holdings and others have repurchased shares, with TENCENT spending 0.703 billion HKD.

According to a document disclosed by HKEX on December 23, both TENCENT (00700.HK) and HSBC Holdings (00005.HK) have repurchased shares. ① TENCENT (00700.HK) repurchased 1.65 million ordinary shares on December 20, involving an amount of 0.703 billion HKD, with a repurchase price ranging from 428.2 HKD to 414.2 HKD per share. Since the repurchase authorization resolution, the total number of shares repurchased is 0.223 billion shares, accounting for 2.365% of the number of shares issued at the time the ordinary resolution was passed. ② HSBC Holdings (00005.HK)

Futu NewsDec 23 09:30

Express News | Everbright: Multiple drugs have made progress, and rapid development in the field of liver fibrosis treatment.

BreakingsDec 22 08:19

On December 20, ASCLETIS-B (01672.HK) spent 0.073 million Hong Kong dollars to repurchase 0.029 million shares.

On December 20, Gelonghui reported that ASCLETIS-B (01672.HK) announced the repurchase of 0.029 million shares at a cost of 0.073 million HKD on December 20, 2024.

Gelonghui FinanceDec 20 18:53

[Brokerage Focus] Founder Securities maintains a recommendation rating for Gilead Sciences (01672). ASC47 combined with semaglutide shows better results in weight loss and muscle preservation compared to monotherapy.

Jingwu Financial News | Founder Securities reported that Geely Pharmaceutical (01672) recently announced preclinical weight loss data for its candidate drug ASC47, which is used in combination with Semaglutide to treat obesity. The report indicates that the combination of ASC47 and Semaglutide outperforms Semaglutide alone in both weight loss and the proportion of total muscle mass in preclinical results: In terms of weight loss, the low-dose regimen (ASC47, 3mg/kg, subcutaneous injection, once every four weeks) combined with Semaglutide (30nmol/kg, subcutaneous injection, once daily) shows better results than Semaglutide alone (30nmol/kg, subcutaneous injection).

Kingwu Financial NewsDec 20 14:10 · Ratings

Hong Kong stocks volatility | ASCLETIS-B (01672) rose over 13%. The candidate drug ASC47 for treating obesity shows encouraging efficacy in research.

ASCLETIS-B (01672) rose over 13%, as of the time of writing, it increased by 13.01%, trading at 2.78 Hong Kong dollars, with a transaction amount of 3.1806 million Hong Kong dollars.

Zhitong FinanceDec 20 09:46